live sessions
MST:
Mountain Standard Time
MST
:
Mountain Standard Time
All Sessions
Live Now:
FEB22
8:30 AMto12:30 PMMST
12:00 PMto5:00 PMMST
Scott M. Hammer Workshop for New Researchers and Trainees
8:30 AM8:30 AM
1 - Welcome and Session Overview for the Scott M. Hammer Workshop for New Researchers and Trainees
8:35 AM8:35 AM
Community Perspectives Video
Brian Minalga (Miss Molly Moon)
Fred Hutchinson Cancer Center, Seattle, WA, USA
8:40 AM8:40 AM
What Has the Advent of Capsid Inhibitors Taught Us About HIV Pathogenesis: Navigating Virology Presentations at CROI 2026
Stuart J. D. Neil
King's College London, London, UK
9:03 AM9:03 AM
Questions and Answers
9:18 AM9:18 AM
Community Perspectives Video
Sekgabo Seselamarumo
Sentebale, Gaborone, Botswana
9:23 AM9:23 AM
Immunology of HIV Cure and Beyond: Navigating Immunology Presentations at CROI 2026
John Frater
University of Oxford, Oxford, UK
9:46 AM9:46 AM
Questions and Answers
10:16 AM10:16 AM
Community Perspectives Video
Chilufya Kasanda
CIDRZ (Centre for Infectious Disease Research in Zambia), Lusaka, Zambia
10:21 AM10:21 AM
Long-Acting HIV Treatment Regimens: Where Are We and Where Are We Going? Navigating HIV Treatment Presentations at CROI 2026
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
10:44 AM10:44 AM
Questions and Answers
10:59 AM10:59 AM
Community Perspectives Video
Ricardo Baruch Domninguez
Inspira Cambio A.C., Mexico City, Mexico
11:04 AM11:04 AM
Taking Prevention to the Population Level: Navigating Implementation Science Presentations at CROI 2026
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, USA
11:27 AM11:27 AM
Questions and Answers
11:52 AM11:52 AM
Community Perspectives Video
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
11:57 AM11:57 AM
Reclaiming the Narrative: Navigating Research Through Turbulent Times
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
12:20 PM12:20 PM
Community Perspectives Video
2:00 PM2:00 PM
2 - Spatial Transcriptomic and Proteomic Profiling of HIV in Tissues
Zaza Ndhlovu
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
3 - Integrative Structural and Computational Approaches to RNA Biology
Megan Ken
The Scripps Research Institute, La Jolla, CA, USA
3:00 PM3:00 PM
4 - Latent HIV Reversal via Functional Genomics and Single-Cell Perturbation Modeling
Wei Li
University of Maryland, Baltimore, MD, USA
3:30 PM3:30 PM
5 - Leveraging Artificial Intelligence for Spatial Analysis of Infectious Diseases
Jacob D. Estes
Oregon Health & Science University, Portland, OR, USA
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Contemporary Issues in Clinical Management: A Case-Based Workshop
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Sanjay Bhagani
Royal Free London NHS Foundation Trust, London, UK
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Brenda E. Crabtree-Ramírez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Susanna Naggie
Durham VA Health Care System, Durham, NC, USA
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Clinical Trial Design and Analysis Workshop
2:00 PM2:00 PM
7 - Clinical Trials in the Post-Lenacapavir Era
David V. Glidden
University of California San Francisco, San Francisco, CA, USA
2:35 PM2:35 PM
8 - Measurement of Outcomes in Health Care Delivery: Implementation Trials
Thomas A. Odeny
Washington University, St Louis, MO, USA
3:10 PM3:10 PM
9 - Accounting for User Choice: Preference Trials in HIV Prevention and Treatment Research
Elizabeth R. Brown
Fred Hutchinson Cancer Center, Seattle, WA, USA
5:00 PM5:00 PM
Welcome From the Conference Chair
Nicolas Chomont
Université de Montréal, Montreal, Canada
5:10 PM5:10 PM
Introduction to the Lifetime Achievement Award
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
5:15 PM5:15 PM
Acceptance of the Lifetime Achievement Award
Carl W. Dieffenbach
Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
5:20 PM5:20 PM
Introduction to the Bernard Fields Lecture
Nicolas Chomont
Université de Montréal, Montreal, Canada
5:25 PM5:25 PM
10 - Unfinished Business: Thirty Years of Persistence, Progress, and Partnerships in HIV Cure Science
Sharon R. Lewin
The University of Melbourne, Melbourne, Australia
5:50 PM5:50 PM
Introduction to the Martin Delaney Presentation
Michael Louella
UW/Fred Hutch Center for AIDS Research (CFAR), Seattle, WA, USA
5:55 PM5:55 PM
11 - ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding
Peter Staley
PrEP4All, New York, NY, USA
6:20 PM6:20 PM
Introduction to the N'Galy-Mann Lecture
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
6:25 PM6:25 PM
12 - The ART of Prevention: People, Science, Progress
Linda-Gail Bekker
Desmond Tutu HIV Foundation, Cape Town, South Africa
6:50 PM6:50 PM
Conclusion of the Opening Session and Welcome to the Opening Reception
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
13 - Meeting the Moment: HIV Treatment and Prevention
Ilesh Jani
Mozambique National Institute of Health, Maputo, Mozambique
9:05 AM9:05 AM
14 - Structure, Function, and Inhibition of the HIV Capsid
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Interaction of HIV With Cells and People
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
100 - Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10:13 AM10:13 AM
101 - Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA
Hisashi Akiyama
Boston University, Boston, MA, USA
10:21 AM10:21 AM
102 - RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:29 AM10:29 AM
103 - Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
104 - Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
11:13 AM11:13 AM
105 - Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
106 - Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
11:29 AM11:29 AM
107 - Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model
Stacey A. Smith
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
108 - Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
10:13 AM10:13 AM
109 - Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation
Paraskevas Filippidis
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
110 - Characterization of HIV Proviruses in Brain Microglia in PWH on ART
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
10:29 AM10:29 AM
111 - Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes
Alan Winston
Imperial College London, London, UK
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
112 - Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
11:13 AM11:13 AM
113 - Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
114 - Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies
Claudia Stroupe
Northwestern University, Chicago, IL, USA
11:29 AM11:29 AM
115 - GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa
Miguel Marin
Africa Health Research Institute, Durban, South Africa
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
116 - Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV
Zaayid Omar
University of Cape Town, Cape Town, South Africa
10:13 AM10:13 AM
117 - Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:21 AM10:21 AM
118 - Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
119 - Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
120 - Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
11:13 AM11:13 AM
121 - Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11:21 AM11:21 AM
122 - Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:29 AM11:29 AM
123 - Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
11:37 AM11:37 AM
124 - Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
125 - Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
10:13 AM10:13 AM
126 - MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
10:21 AM10:21 AM
127 - Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
10:29 AM10:29 AM
128 - Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
129 - Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
11:13 AM11:13 AM
130 - Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
11:21 AM11:21 AM
131 - RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:29 AM11:29 AM
132 - Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Mechanisms and Modifiers: Treatable Causes of Cognitive Impairment and Depression
1:30 PM1:30 PM
Session Overview
Leah H. Rubin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
453 - MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study
Katekarn Porkaew
Chulalongkorn University, Bangkok, Thailand
1:38 PM1:38 PM
451 - Metabolic Syndrome and Cognitive Impairment Among Men With and Without HIV
Sara M. Hockney
Northwestern University, Chicago, IL, USA
1:42 PM1:42 PM
448 - Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Female Individuals
Elana Farrell
University of California San Francisco, San Francisco, CA, USA
1:46 PM1:46 PM
447 - The Impact of Semaglutide on Depressive Symptoms Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
New Host Factors: Regulating Nuclear Events of HIV Replication
1:30 PM1:30 PM
Session Overview
Edward Campbell
Loyola University Chicago, Chicago, IL, USA
1:34 PM1:34 PM
217 - BLM Helicase Is Required for Efficient HIV Infection in Macrophages
Andrew Leal
Boston University, Boston, MA, USA
1:38 PM1:38 PM
218 - CD46 Interacts With Sp1 to Control HIV Expression in Infected T Cells
Pavitra Ramdas
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
1:42 PM1:42 PM
216 - Exploring the Role of FUBP1 in HIV Replication and Latency
Fiona Carter-Tod
Northwestern University, Chicago, IL, USA
1:46 PM1:46 PM
214 - Cis- and Trans-Acting Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts
Anthony Boateng
Washington University in St Louis, St Louis, MO, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Noncanonical Mutations Conferring Resistance to InSTIs
1:30 PM1:30 PM
Session Overview
Daniel R. Kuritzkes
Harvard Medical School, Boston, MA, USA
1:34 PM1:34 PM
551 - Env Mutations Are a Gateway for Acquisition of InSTI Resistance
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
1:38 PM1:38 PM
585 - Nucleocapsid Mutations During Virologic Failure of an Integrase Inhibitor-Based Regimen
Charlotte Charpentier
Assistance Publique – Hôpitaux de Paris, Paris, France
1:42 PM1:42 PM
553 - Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure
Nicola Coetzee
Stellenbosch University, Cape Town, South Africa
1:46 PM1:46 PM
550 - Characterization of Mutations Outside the Integrase in HIV-1 Individuals in Whom Dolutegravir Failed
Aurelie Minelle Kengni Ngueko
Centre International de Référence Chantal Biya, Yaoundé, Cameroon
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Sleepless in Denver: Impact of Funding Changes on HIV Care
1:30 PM1:30 PM
Session Overview
Jennifer Kates
Kaiser Family Foundation, Washington, DC, USA
1:38 PM1:38 PM
1051 - Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries
Ellen Brazier
Institute for Implementation Science in Population Health, New York, NY, USA
1:42 PM1:42 PM
1054 - Population-Representative Consequences of Foreign Aid Instability for HIV Services in South Africa
Lindsey Filiatreau
Washington University in St Louis, St Louis, MO, USA
1:46 PM1:46 PM
1107 - Short-Term Poverty Relief and ART Adherence: Insights From a Natural Experiment of SNAP Recipients
Aaron Richterman
University of Pennsylvania, Philadelphia, PA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
4:00 PM4:00 PM
5-Minute Moderator Opening: Background and Setting the Stage
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
4:05 PM4:05 PM
15 - Integrase Anchors Viral RNA to the HIV-1 Capsid Interior
Peter Cherepanov
The Francis Crick Institute, London, UK
4:25 PM4:25 PM
16 - Capsid-Mediated Protection of HIV-1 Nucleic Acids From Innate Immune Detection
Sebla Kutluay
Washington University in St Louis, St Louis, MO, USA
4:45 PM4:45 PM
17 - HIV-1 Uncoating Site Dictates Sites of Integration
Vinay K. Pathak
National Cancer Institute at Frederick, Frederick, MD, USA
5:05 PM5:05 PM
Questions and Answers
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV
4:00 PM4:00 PM
18 - Neurodegeneration and Dementia Risk in Older Adults With HIV: Biomarkers and Epidemiology
Alan Winston
Imperial College London, London, UK
4:20 PM4:20 PM
19 - Epigenetic Aging of the Brain in HIV: Methylation Clocks and Antiretroviral-Related Changes
Michael J. Corley
University of California San Diego Medical Center, La Jolla, CA, USA
4:40 PM4:40 PM
20 - Cognitive Aging in HIV: Clinical Assessment and Management
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Questions and Answers
Paola M. P. Cinque
IRCCS San Raffaele Scientific Institute, Milan, Italy
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Strategic and Resilient Responses to the Funding Crisis Across Africa
4:00 PM4:00 PM
21 - Sustaining Successful HIV Programs Across Africa: The Impact of Shifts in Funding
Geoff P. Garnett
London School of Hygiene & Tropical Medicine, London, UK
4:20 PM4:20 PM
22 - Global Cuts, Local Consequences: Community Impact and Response to the HIV Funding Crisis
Solange L. Baptiste
ITPC Global, Johannesburg, South Africa
4:40 PM4:40 PM
23 - Circumventing the Cascading Crisis: Impacts of US Government Policies on Research and Adaptations in Africa
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestLastName 4
Institution 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
24 - GLP-1 Receptor Agonists: Are They a Cure for Everything?
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9:05 AM9:05 AM
25 - Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
133 - A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
10:13 AM10:13 AM
134 - Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B
Julia Edgar
University of Oxford, Oxford, UK
10:21 AM10:21 AM
135 - Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control
Katie Fisher
Aarhus University, Aarhus, Denmark
10:29 AM10:29 AM
136 - Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
137 - CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
11:13 AM11:13 AM
138 - Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
139 - Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
140 - Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
141 - Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results
David Wyles
Denver Health Medical Center, Denver, CO, USA
10:13 AM10:13 AM
142 - Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy
Grace Haser
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
143 - Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
144 - Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
145 - One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
11:13 AM11:13 AM
146 - Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis
Sean Wasserman
St George's University of London, London, UK
11:21 AM11:21 AM
147 - DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
11:29 AM11:29 AM
148 - Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
11:37 AM11:37 AM
149 - Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
150 - DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
151 - Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
10:21 AM10:21 AM
152 - Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
153 - Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
154 - DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
11:13 AM11:13 AM
155 - Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
11:21 AM11:21 AM
156 - Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention
Brian Zanoni
Emory University, Atlanta, GA, USA
11:29 AM11:29 AM
157 - Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
We Thought You'd Never Ask: Improving HIV Screening and Testing
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
158 - Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
10:13 AM10:13 AM
159 - Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers
Timothy Long MD
Health Choice Network, Miami, FL, USA
10:21 AM10:21 AM
160 - Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US
David E. Hudon
Prisma Health, Greenville, SC, USA
10:29 AM10:29 AM
161 - Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
162 - Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025
Andrew Hill
University of Liverpool, Liverpool, UK
11:13 AM11:13 AM
163 - The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
164 - Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial
Paul K. Drain
University of Washington, Seattle, WA, USA
11:29 AM11:29 AM
165 - Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Targeting the HIV Reservoir: Novel Cure Strategies
1:30 PM1:30 PM
Session Overview
Marina Caskey
The Rockefeller University, New York, NY, USA
1:34 PM1:34 PM
406 - Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles
Keely Gliwa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo
David D. Ho
Aaron Diamond AIDS Research Center, New York, NY, USA
1:42 PM1:42 PM
407 - Combination Therapy With Tat mRNA and a TLR9 Agonist Delays Post-ATI Rebound in the NHP Model
Takuto Nogimori
National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
1:46 PM1:46 PM
408 - Markedly Reduced Mutability of Networked Epitopes Promotes CTL Clearance of the Latent HIV Reservoir
Fernando B. Senjobe
Harvard Medical School, Boston, MA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Extra Large Challenges in Steatotic Liver Disease
1:30 PM1:30 PM
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
599 - Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
1:38 PM1:38 PM
600 - Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
1:42 PM1:42 PM
598 - Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
1:46 PM1:46 PM
601 - Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV
Jimmy Ma
University of Washington, Seattle, WA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
1:30 PM1:30 PM
Session Overview
Suzue Saito
ICAP at Columbia University, New York, NY, USA
1:34 PM1:34 PM
903 - Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia
Michael Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:38 PM1:38 PM
890 - Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina
Ann Dennis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:42 PM1:42 PM
894 - Mapping Recent HIV Infections Among MSM in Thailand: Data-Driven Insights for Targeted Prevention
Michael Reid
1:46 PM1:46 PM
922 - Progress Towards HIV Epidemic Control Among Young Key Populations in India
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
1:30 PM1:30 PM
Session Overview
Ravi Goyal
University of California San Diego, La Jolla, CA, USA
1:34 PM1:34 PM
1077 - Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025
Ndinda Christian
Rwanda Biomedical Centre, Kigali, Rwanda
1:38 PM1:38 PM
1076 - Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits
Joseph W. Hogan
Brown University, Providence, RI, USA
1:42 PM1:42 PM
1079 - Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya
Jessica Haberer
Massachusetts General Hospital, Boston, MA, USA
1:46 PM1:46 PM
1078 - Measuring Provider Quality of Care in Tanzania Using Large Language Models
Alaa Abdellatif
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
30 Years of Viral Suppression: A Biologic Reset?
4:00 PM4:00 PM
26 - HIV Reservoir: Persistence and Expansion Under Long-Term ART
John W. Mellors
University of Pittsburgh, Pittsburgh, PA, USA
4:20 PM4:20 PM
27 - HIV-Specific T-Cell Responses in People With HIV on Long-Term ART
Victor Appay
University of Bordeaux, Bordeaux, France
4:40 PM4:40 PM
28 - Beyond Undetectable: Chronic Inflammation and Multimorbidity in People With HIV on ART
Irini Sereti
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
5:00 PM5:00 PM
Questions and Answers
Michael M. Lederman
Case Western Reserve University, Cleveland, OH, USA
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
The Long Game: Progress and the Promise of Long-Acting ART for Treatment
4:00 PM4:00 PM
29 - Clinical Trials and New Drugs in the Pipeline
Onyema Ogbuagu
Yale University, New Haven, CT, USA
4:20 PM4:20 PM
30 - Challenges and Solutions to Implementation
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
4:40 PM4:40 PM
Panel Discussion
Eric S. Daar
University of California Los Angeles, Los Angeles, CA, USA
4:40 PM4:40 PM
Panel Discussion
Gastón Devisich
Fundación Huésped, Buenos Aires, Argentina
4:40 PM4:40 PM
Panel Discussion
Rosie Mngqibisa
Enhancing Care Foundation, Durban, South Africa
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Counting and Caring for Transgender and Gender-Diverse Individuals
4:00 PM4:00 PM
31 - Epidemiology
Stefan Baral
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:20 PM4:20 PM
32 - Clinical Management
Asa E. Radix
Callen-Lorde Community Health Center, New York, NY, USA
4:40 PM4:40 PM
33 - Community Evidence, System Change: Transgender Leadership in Sustaining HIV Care
Rena Janamnuaysook
Institute of HIV Research and Innovation, Bangkok, Thailand
5:00 PM5:00 PM
Questions and Answers
Jade Ghosn
Assistance Publique – Hôpitaux de Paris, Paris, France
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
8:35 AM8:35 AM
34 - Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
9:05 AM9:05 AM
35 - Tuberculosis in Children and Adolescents: From Neglect to Action
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Manipulating the HIV Immune Response for Prevention and Treatment
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
166 - Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:13 AM10:13 AM
167 - Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
168 - In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
169 - Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
170 - Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:13 AM11:13 AM
171 - A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
172 - Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:29 AM11:29 AM
173 - Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART
Mirko Paiardini
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Extending the Reach: Long-Acting Antiviral and Novel Delivery
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
174 - Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
10:13 AM10:13 AM
175 - Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing
Nilay Thakkar
GSK plc, Collegeville, PA, USA
10:21 AM10:21 AM
176 - Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back
GSK plc, Collegeville, PA, USA
10:29 AM10:29 AM
177 - DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
178 - Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
11:13 AM11:13 AM
179 - Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
11:21 AM11:21 AM
180 - Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
181 - Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1
Chloe M. Orkin
Queen Mary University of London, London, UK
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Good to Great: Advancing Treatment and Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
182 - HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
10:13 AM10:13 AM
183 - Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
10:21 AM10:21 AM
184 - The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants
Adam W. Carrico
Florida International University, Miami, FL, USA
10:29 AM10:29 AM
185 - Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma
Kathleen J. Sikkema
Columbia University, New York, NY, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
186 - SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
11:13 AM11:13 AM
187 - Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation
Deborah Hoege
Georgetown University, Washington, DC, USA
11:21 AM11:21 AM
188 - Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
11:29 AM11:29 AM
189 - Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial
Chris T. Longenecker
University of Washington, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Partners, Pills, and Penicillin: Progress in Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
190 - Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25
Chase A. Cannon
University of Washington, Seattle, WA, USA
10:13 AM10:13 AM
191 - HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
192 - HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
10:29 AM10:29 AM
193 - Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
194 - Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
11:13 AM11:13 AM
195 - Early Syphilis and HIV Among Adolescents: United States, 20142-023
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:21 AM11:21 AM
196 - Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
11:29 AM11:29 AM
197 - Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men
Kate L. Seib
Griffith University, Southport, Australia
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Harnessing B-Cells and Antibodies for HIV Control
1:30 PM1:30 PM
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
1:34 PM1:34 PM
294 - AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques
Luanna E. L. Vidal
University of Miami, Miami, FL, USA
1:38 PM1:38 PM
295 - Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
1:42 PM1:42 PM
296 - Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control
Elif Cakan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:46 PM1:46 PM
297 - Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI
Julia A. Wagner
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Tuberculosis: Innovative Screening and Diagnostic Approaches
1:30 PM1:30 PM
Session Overview
Yukari C. Manabe
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
773 - Efficiency of Portable Chest X-Ray Compared to Symptom-Based TB Screening in Southwest Nigeria
Aderonke V. Agbaje
Institute of Human Virology Nigeria, Abuja, Nigeria
1:38 PM1:38 PM
774 - High Prevalence of Asymptomatic Tuberculosis in an African Cohort of People With HIV (CoVPN 3008-TB)
Asa Tapley
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
775 - The Case for Routine Testing and Empiric Treatment of TB Meningitis in High HIV-Prevalence Settings
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
1:46 PM1:46 PM
776 - Very Promising New Urinary LAM Assay for Tuberculosis Diagnosis in Children
Adeline Riondel
French National Institute of Health and Medical Research (Inserm), Paris, France
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Advancing Mental Health for Youth With HIV
1:30 PM1:30 PM
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
1:34 PM1:34 PM
871 - Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
872 - Implementation of a Mental Health Intervention for Youth With HIV in Kenya
Pamela Kohler
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
874 - Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
1:46 PM1:46 PM
873 - Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Some Assembly Required: Self-Blood Collection and Testing
1:30 PM1:30 PM
Session Overview
Michelle Rodolph
World Health Organization, Geneva, Switzerland
1:34 PM1:34 PM
975 - Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa
Alexandra de Nooy
Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
1:38 PM1:38 PM
974 - HIV Self-Testing by Motorcycle-Taxi Drivers: A Novel Approach for Case Detection in Kampala, Uganda
Edith Namulema
Mengo Hospital, Kampala, Uganda
1:42 PM1:42 PM
977 - Virtual Submission of HIV Viral Load in EPI-LoVE, a Digital Cohort of People Living With HIV in US
Pamina M. Gorbach
University of California Los Angeles, Los Angeles, CA, USA
1:46 PM1:46 PM
976 - Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms
David Closs
Friends for All, Memphis, TN, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Masters of Immunity: The Many Faces of T Cells
4:00 PM4:00 PM
36 - Nonconventional T Cells: Functional Shape Shifters and Conductors of Cytokine Orchestras That Dance With Herpesviruses in People With HIV
Jennifer Snyder-Cappione
Boston University, Boston, MA, USA
4:20 PM4:20 PM
37 - The T-Cell Identity: Conventional T Cells in Action
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
4:40 PM4:40 PM
38 - Engineering T Cells: Improving on Nature
Anjie Zhen
University of California Los Angeles, Los Angeles, CA, USA
5:00 PM5:00 PM
Questions and Answers
Pamela J. Skinner
University of Minnesota, Minneapolis, MN, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Time for a Paradigm Shift for Young Pregnant and Breastfeeding Cisgender Women
4:00 PM4:00 PM
39 - HIV Prevention and Treatment Among Young Mothers: Dynamics of Biologic, Psychosocial, and Structural Determinants Across the Life Course
Elona Toska
University of Cape Town, Cape Town, South Africa
4:20 PM4:20 PM
40 - Continuity of Care During Pregnancy and Postpartum
Aleny Couto
Ministry of Health of Mozambique, Maputo, Mozambique
4:40 PM4:40 PM
41 - Ethical and Regulatory System Changes for the Inclusion of Pregnant Women in HIV Research and Development
Cordelia Katureebe
Ministry of Health Uganda, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Lynn T. Matthews
Yale University, New Haven, CT, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Hot Takes on the Clinical Highlights From CROI 2026
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Joseph J. Eron, Jr
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Fatima Kakkar
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Chloe M. Orkin
Queen Mary University of London, London, UK
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Deborah Persaud
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Paul E. Sax
Brigham and Women's Hospital, Boston, MA, USA
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
Upcoming:
FEB22
8:30 AMto12:30 PMMST
12:00 PMto5:00 PMMST
Scott M. Hammer Workshop for New Researchers and Trainees
8:30 AM8:30 AM
1 - Welcome and Session Overview for the Scott M. Hammer Workshop for New Researchers and Trainees
8:35 AM8:35 AM
Community Perspectives Video
Brian Minalga (Miss Molly Moon)
Fred Hutchinson Cancer Center, Seattle, WA, USA
8:40 AM8:40 AM
What Has the Advent of Capsid Inhibitors Taught Us About HIV Pathogenesis: Navigating Virology Presentations at CROI 2026
Stuart J. D. Neil
King's College London, London, UK
9:03 AM9:03 AM
Questions and Answers
9:18 AM9:18 AM
Community Perspectives Video
Sekgabo Seselamarumo
Sentebale, Gaborone, Botswana
9:23 AM9:23 AM
Immunology of HIV Cure and Beyond: Navigating Immunology Presentations at CROI 2026
John Frater
University of Oxford, Oxford, UK
9:46 AM9:46 AM
Questions and Answers
10:16 AM10:16 AM
Community Perspectives Video
Chilufya Kasanda
CIDRZ (Centre for Infectious Disease Research in Zambia), Lusaka, Zambia
10:21 AM10:21 AM
Long-Acting HIV Treatment Regimens: Where Are We and Where Are We Going? Navigating HIV Treatment Presentations at CROI 2026
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
10:44 AM10:44 AM
Questions and Answers
10:59 AM10:59 AM
Community Perspectives Video
Ricardo Baruch Domninguez
Inspira Cambio A.C., Mexico City, Mexico
11:04 AM11:04 AM
Taking Prevention to the Population Level: Navigating Implementation Science Presentations at CROI 2026
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, USA
11:27 AM11:27 AM
Questions and Answers
11:52 AM11:52 AM
Community Perspectives Video
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
11:57 AM11:57 AM
Reclaiming the Narrative: Navigating Research Through Turbulent Times
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
12:20 PM12:20 PM
Community Perspectives Video
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Laboratory Sciences
2:00 PM2:00 PM
2 - Spatial Transcriptomic and Proteomic Profiling of HIV in Tissues
Zaza Ndhlovu
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
3 - Integrative Structural and Computational Approaches to RNA Biology
Megan Ken
The Scripps Research Institute, La Jolla, CA, USA
3:00 PM3:00 PM
4 - Latent HIV Reversal via Functional Genomics and Single-Cell Perturbation Modeling
Wei Li
University of Maryland, Baltimore, MD, USA
3:30 PM3:30 PM
5 - Leveraging Artificial Intelligence for Spatial Analysis of Infectious Diseases
Jacob D. Estes
Oregon Health & Science University, Portland, OR, USA
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Contemporary Issues in Clinical Management: A Case-Based Workshop
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Sanjay Bhagani
Royal Free London NHS Foundation Trust, London, UK
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Brenda E. Crabtree-Ramírez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Susanna Naggie
Durham VA Health Care System, Durham, NC, USA
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Clinical Trial Design and Analysis Workshop
2:00 PM2:00 PM
7 - Clinical Trials in the Post-Lenacapavir Era
David V. Glidden
University of California San Francisco, San Francisco, CA, USA
2:35 PM2:35 PM
8 - Measurement of Outcomes in Health Care Delivery: Implementation Trials
Thomas A. Odeny
Washington University, St Louis, MO, USA
3:10 PM3:10 PM
9 - Accounting for User Choice: Preference Trials in HIV Prevention and Treatment Research
Elizabeth R. Brown
Fred Hutchinson Cancer Center, Seattle, WA, USA
FEB22
5:00 PMto7:00 PMMST
12:00 PMto5:00 PMMST
Opening Session
5:00 PM5:00 PM
Welcome From the Conference Chair
Nicolas Chomont
Université de Montréal, Montreal, Canada
5:10 PM5:10 PM
Introduction to the Lifetime Achievement Award
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
5:15 PM5:15 PM
Acceptance of the Lifetime Achievement Award
Carl W. Dieffenbach
Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
5:20 PM5:20 PM
Introduction to the Bernard Fields Lecture
Nicolas Chomont
Université de Montréal, Montreal, Canada
5:25 PM5:25 PM
10 - Unfinished Business: Thirty Years of Persistence, Progress, and Partnerships in HIV Cure Science
Sharon R. Lewin
The University of Melbourne, Melbourne, Australia
5:50 PM5:50 PM
Introduction to the Martin Delaney Presentation
Michael Louella
UW/Fred Hutch Center for AIDS Research (CFAR), Seattle, WA, USA
5:55 PM5:55 PM
11 - ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding
Peter Staley
PrEP4All, New York, NY, USA
6:20 PM6:20 PM
Introduction to the N'Galy-Mann Lecture
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
6:25 PM6:25 PM
12 - The ART of Prevention: People, Science, Progress
Linda-Gail Bekker
Desmond Tutu HIV Foundation, Cape Town, South Africa
6:50 PM6:50 PM
Conclusion of the Opening Session and Welcome to the Opening Reception
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
FEB22
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
FEB22
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
FEB23
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
13 - Meeting the Moment: HIV Treatment and Prevention
Ilesh Jani
Mozambique National Institute of Health, Maputo, Mozambique
9:05 AM9:05 AM
14 - Structure, Function, and Inhibition of the HIV Capsid
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Interaction of HIV With Cells and People
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
100 - Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10:13 AM10:13 AM
101 - Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA
Hisashi Akiyama
Boston University, Boston, MA, USA
10:21 AM10:21 AM
102 - RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:29 AM10:29 AM
103 - Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
104 - Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
11:13 AM11:13 AM
105 - Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
106 - Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
11:29 AM11:29 AM
107 - Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model
Stacey A. Smith
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
108 - Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
10:13 AM10:13 AM
109 - Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation
Paraskevas Filippidis
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
110 - Characterization of HIV Proviruses in Brain Microglia in PWH on ART
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
10:29 AM10:29 AM
111 - Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes
Alan Winston
Imperial College London, London, UK
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
112 - Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
11:13 AM11:13 AM
113 - Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
114 - Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies
Claudia Stroupe
Northwestern University, Chicago, IL, USA
11:29 AM11:29 AM
115 - GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa
Miguel Marin
Africa Health Research Institute, Durban, South Africa
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
116 - Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV
Zaayid Omar
University of Cape Town, Cape Town, South Africa
10:13 AM10:13 AM
117 - Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:21 AM10:21 AM
118 - Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
119 - Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
120 - Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
11:13 AM11:13 AM
121 - Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11:21 AM11:21 AM
122 - Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:29 AM11:29 AM
123 - Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
11:37 AM11:37 AM
124 - Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
125 - Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
10:13 AM10:13 AM
126 - MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
10:21 AM10:21 AM
127 - Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
10:29 AM10:29 AM
128 - Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
129 - Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
11:13 AM11:13 AM
130 - Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
11:21 AM11:21 AM
131 - RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:29 AM11:29 AM
132 - Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Mechanisms and Modifiers: Treatable Causes of Cognitive Impairment and Depression
1:30 PM1:30 PM
Session Overview
Leah H. Rubin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
453 - MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study
Katekarn Porkaew
Chulalongkorn University, Bangkok, Thailand
1:38 PM1:38 PM
451 - Metabolic Syndrome and Cognitive Impairment Among Men With and Without HIV
Sara M. Hockney
Northwestern University, Chicago, IL, USA
1:42 PM1:42 PM
448 - Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Female Individuals
Elana Farrell
University of California San Francisco, San Francisco, CA, USA
1:46 PM1:46 PM
447 - The Impact of Semaglutide on Depressive Symptoms Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
New Host Factors: Regulating Nuclear Events of HIV Replication
1:30 PM1:30 PM
Session Overview
Edward Campbell
Loyola University Chicago, Chicago, IL, USA
1:34 PM1:34 PM
217 - BLM Helicase Is Required for Efficient HIV Infection in Macrophages
Andrew Leal
Boston University, Boston, MA, USA
1:38 PM1:38 PM
218 - CD46 Interacts With Sp1 to Control HIV Expression in Infected T Cells
Pavitra Ramdas
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
1:42 PM1:42 PM
216 - Exploring the Role of FUBP1 in HIV Replication and Latency
Fiona Carter-Tod
Northwestern University, Chicago, IL, USA
1:46 PM1:46 PM
214 - Cis- and Trans-Acting Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts
Anthony Boateng
Washington University in St Louis, St Louis, MO, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Noncanonical Mutations Conferring Resistance to InSTIs
1:30 PM1:30 PM
Session Overview
Daniel R. Kuritzkes
Harvard Medical School, Boston, MA, USA
1:34 PM1:34 PM
551 - Env Mutations Are a Gateway for Acquisition of InSTI Resistance
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
1:38 PM1:38 PM
585 - Nucleocapsid Mutations During Virologic Failure of an Integrase Inhibitor-Based Regimen
Charlotte Charpentier
Assistance Publique – Hôpitaux de Paris, Paris, France
1:42 PM1:42 PM
553 - Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure
Nicola Coetzee
Stellenbosch University, Cape Town, South Africa
1:46 PM1:46 PM
550 - Characterization of Mutations Outside the Integrase in HIV-1 Individuals in Whom Dolutegravir Failed
Aurelie Minelle Kengni Ngueko
Centre International de Référence Chantal Biya, Yaoundé, Cameroon
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Sleepless in Denver: Impact of Funding Changes on HIV Care
1:30 PM1:30 PM
Session Overview
Jennifer Kates
Kaiser Family Foundation, Washington, DC, USA
1:38 PM1:38 PM
1051 - Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries
Ellen Brazier
Institute for Implementation Science in Population Health, New York, NY, USA
1:42 PM1:42 PM
1054 - Population-Representative Consequences of Foreign Aid Instability for HIV Services in South Africa
Lindsey Filiatreau
Washington University in St Louis, St Louis, MO, USA
1:46 PM1:46 PM
1107 - Short-Term Poverty Relief and ART Adherence: Insights From a Natural Experiment of SNAP Recipients
Aaron Richterman
University of Pennsylvania, Philadelphia, PA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
In and Out of the Capsid
4:00 PM4:00 PM
5-Minute Moderator Opening: Background and Setting the Stage
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
4:05 PM4:05 PM
15 - Integrase Anchors Viral RNA to the HIV-1 Capsid Interior
Peter Cherepanov
The Francis Crick Institute, London, UK
4:25 PM4:25 PM
16 - Capsid-Mediated Protection of HIV-1 Nucleic Acids From Innate Immune Detection
Sebla Kutluay
Washington University in St Louis, St Louis, MO, USA
4:45 PM4:45 PM
17 - HIV-1 Uncoating Site Dictates Sites of Integration
Vinay K. Pathak
National Cancer Institute at Frederick, Frederick, MD, USA
5:05 PM5:05 PM
Questions and Answers
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV
4:00 PM4:00 PM
18 - Neurodegeneration and Dementia Risk in Older Adults With HIV: Biomarkers and Epidemiology
Alan Winston
Imperial College London, London, UK
4:20 PM4:20 PM
19 - Epigenetic Aging of the Brain in HIV: Methylation Clocks and Antiretroviral-Related Changes
Michael J. Corley
University of California San Diego Medical Center, La Jolla, CA, USA
4:40 PM4:40 PM
20 - Cognitive Aging in HIV: Clinical Assessment and Management
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Questions and Answers
Paola M. P. Cinque
IRCCS San Raffaele Scientific Institute, Milan, Italy
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Strategic and Resilient Responses to the Funding Crisis Across Africa
4:00 PM4:00 PM
21 - Sustaining Successful HIV Programs Across Africa: The Impact of Shifts in Funding
Geoff P. Garnett
London School of Hygiene & Tropical Medicine, London, UK
4:20 PM4:20 PM
22 - Global Cuts, Local Consequences: Community Impact and Response to the HIV Funding Crisis
Solange L. Baptiste
ITPC Global, Johannesburg, South Africa
4:40 PM4:40 PM
23 - Circumventing the Cascading Crisis: Impacts of US Government Policies on Research and Adaptations in Africa
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestLastName 4
Institution 4
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
FEB24
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
24 - GLP-1 Receptor Agonists: Are They a Cure for Everything?
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9:05 AM9:05 AM
25 - Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
133 - A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
10:13 AM10:13 AM
134 - Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B
Julia Edgar
University of Oxford, Oxford, UK
10:21 AM10:21 AM
135 - Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control
Katie Fisher
Aarhus University, Aarhus, Denmark
10:29 AM10:29 AM
136 - Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
137 - CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
11:13 AM11:13 AM
138 - Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
139 - Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
140 - Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
141 - Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results
David Wyles
Denver Health Medical Center, Denver, CO, USA
10:13 AM10:13 AM
142 - Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy
Grace Haser
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
143 - Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
144 - Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
145 - One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
11:13 AM11:13 AM
146 - Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis
Sean Wasserman
St George's University of London, London, UK
11:21 AM11:21 AM
147 - DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
11:29 AM11:29 AM
148 - Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
11:37 AM11:37 AM
149 - Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
150 - DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
151 - Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
10:21 AM10:21 AM
152 - Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
153 - Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
154 - DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
11:13 AM11:13 AM
155 - Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
11:21 AM11:21 AM
156 - Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention
Brian Zanoni
Emory University, Atlanta, GA, USA
11:29 AM11:29 AM
157 - Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
We Thought You'd Never Ask: Improving HIV Screening and Testing
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
158 - Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
10:13 AM10:13 AM
159 - Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers
Timothy Long MD
Health Choice Network, Miami, FL, USA
10:21 AM10:21 AM
160 - Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US
David E. Hudon
Prisma Health, Greenville, SC, USA
10:29 AM10:29 AM
161 - Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
162 - Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025
Andrew Hill
University of Liverpool, Liverpool, UK
11:13 AM11:13 AM
163 - The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
164 - Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial
Paul K. Drain
University of Washington, Seattle, WA, USA
11:29 AM11:29 AM
165 - Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Targeting the HIV Reservoir: Novel Cure Strategies
1:30 PM1:30 PM
Session Overview
Marina Caskey
The Rockefeller University, New York, NY, USA
1:34 PM1:34 PM
406 - Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles
Keely Gliwa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo
David D. Ho
Aaron Diamond AIDS Research Center, New York, NY, USA
1:42 PM1:42 PM
407 - Combination Therapy With Tat mRNA and a TLR9 Agonist Delays Post-ATI Rebound in the NHP Model
Takuto Nogimori
National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
1:46 PM1:46 PM
408 - Markedly Reduced Mutability of Networked Epitopes Promotes CTL Clearance of the Latent HIV Reservoir
Fernando B. Senjobe
Harvard Medical School, Boston, MA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Extra Large Challenges in Steatotic Liver Disease
1:30 PM1:30 PM
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
599 - Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
1:38 PM1:38 PM
600 - Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
1:42 PM1:42 PM
598 - Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
1:46 PM1:46 PM
601 - Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV
Jimmy Ma
University of Washington, Seattle, WA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Precision Comes to Public Health
1:30 PM1:30 PM
Session Overview
Suzue Saito
ICAP at Columbia University, New York, NY, USA
1:34 PM1:34 PM
903 - Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia
Michael Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:38 PM1:38 PM
890 - Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina
Ann Dennis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:42 PM1:42 PM
894 - Mapping Recent HIV Infections Among MSM in Thailand: Data-Driven Insights for Targeted Prevention
Michael Reid
1:46 PM1:46 PM
922 - Progress Towards HIV Epidemic Control Among Young Key Populations in India
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Machines, Models, and Messages
1:30 PM1:30 PM
Session Overview
Ravi Goyal
University of California San Diego, La Jolla, CA, USA
1:34 PM1:34 PM
1077 - Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025
Ndinda Christian
Rwanda Biomedical Centre, Kigali, Rwanda
1:38 PM1:38 PM
1076 - Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits
Joseph W. Hogan
Brown University, Providence, RI, USA
1:42 PM1:42 PM
1079 - Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya
Jessica Haberer
Massachusetts General Hospital, Boston, MA, USA
1:46 PM1:46 PM
1078 - Measuring Provider Quality of Care in Tanzania Using Large Language Models
Alaa Abdellatif
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
30 Years of Viral Suppression: A Biologic Reset?
4:00 PM4:00 PM
26 - HIV Reservoir: Persistence and Expansion Under Long-Term ART
John W. Mellors
University of Pittsburgh, Pittsburgh, PA, USA
4:20 PM4:20 PM
27 - HIV-Specific T-Cell Responses in People With HIV on Long-Term ART
Victor Appay
University of Bordeaux, Bordeaux, France
4:40 PM4:40 PM
28 - Beyond Undetectable: Chronic Inflammation and Multimorbidity in People With HIV on ART
Irini Sereti
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
5:00 PM5:00 PM
Questions and Answers
Michael M. Lederman
Case Western Reserve University, Cleveland, OH, USA
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
The Long Game: Progress and the Promise of Long-Acting ART for Treatment
4:00 PM4:00 PM
29 - Clinical Trials and New Drugs in the Pipeline
Onyema Ogbuagu
Yale University, New Haven, CT, USA
4:20 PM4:20 PM
30 - Challenges and Solutions to Implementation
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
4:40 PM4:40 PM
Panel Discussion
Eric S. Daar
University of California Los Angeles, Los Angeles, CA, USA
4:40 PM4:40 PM
Panel Discussion
Gastón Devisich
Fundación Huésped, Buenos Aires, Argentina
4:40 PM4:40 PM
Panel Discussion
Rosie Mngqibisa
Enhancing Care Foundation, Durban, South Africa
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Counting and Caring for Transgender and Gender-Diverse Individuals
4:00 PM4:00 PM
31 - Epidemiology
Stefan Baral
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:20 PM4:20 PM
32 - Clinical Management
Asa E. Radix
Callen-Lorde Community Health Center, New York, NY, USA
4:40 PM4:40 PM
33 - Community Evidence, System Change: Transgender Leadership in Sustaining HIV Care
Rena Janamnuaysook
Institute of HIV Research and Innovation, Bangkok, Thailand
5:00 PM5:00 PM
Questions and Answers
Jade Ghosn
Assistance Publique – Hôpitaux de Paris, Paris, France
FEB24
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
FEB25
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Wednesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
8:35 AM8:35 AM
34 - Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
9:05 AM9:05 AM
35 - Tuberculosis in Children and Adolescents: From Neglect to Action
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Manipulating the HIV Immune Response for Prevention and Treatment
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
166 - Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:13 AM10:13 AM
167 - Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
168 - In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
169 - Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
170 - Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:13 AM11:13 AM
171 - A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
172 - Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:29 AM11:29 AM
173 - Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART
Mirko Paiardini
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Extending the Reach: Long-Acting Antiviral and Novel Delivery
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
174 - Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
10:13 AM10:13 AM
175 - Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing
Nilay Thakkar
GSK plc, Collegeville, PA, USA
10:21 AM10:21 AM
176 - Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back
GSK plc, Collegeville, PA, USA
10:29 AM10:29 AM
177 - DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
178 - Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
11:13 AM11:13 AM
179 - Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
11:21 AM11:21 AM
180 - Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
181 - Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1
Chloe M. Orkin
Queen Mary University of London, London, UK
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Good to Great: Advancing Treatment and Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
182 - HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
10:13 AM10:13 AM
183 - Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
10:21 AM10:21 AM
184 - The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants
Adam W. Carrico
Florida International University, Miami, FL, USA
10:29 AM10:29 AM
185 - Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma
Kathleen J. Sikkema
Columbia University, New York, NY, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
186 - SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
11:13 AM11:13 AM
187 - Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation
Deborah Hoege
Georgetown University, Washington, DC, USA
11:21 AM11:21 AM
188 - Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
11:29 AM11:29 AM
189 - Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial
Chris T. Longenecker
University of Washington, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Partners, Pills, and Penicillin: Progress in Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
190 - Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25
Chase A. Cannon
University of Washington, Seattle, WA, USA
10:13 AM10:13 AM
191 - HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
192 - HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
10:29 AM10:29 AM
193 - Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
194 - Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
11:13 AM11:13 AM
195 - Early Syphilis and HIV Among Adolescents: United States, 20142-023
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:21 AM11:21 AM
196 - Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
11:29 AM11:29 AM
197 - Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men
Kate L. Seib
Griffith University, Southport, Australia
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Harnessing B-Cells and Antibodies for HIV Control
1:30 PM1:30 PM
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
1:34 PM1:34 PM
294 - AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques
Luanna E. L. Vidal
University of Miami, Miami, FL, USA
1:38 PM1:38 PM
295 - Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
1:42 PM1:42 PM
296 - Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control
Elif Cakan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:46 PM1:46 PM
297 - Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI
Julia A. Wagner
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Tuberculosis: Innovative Screening and Diagnostic Approaches
1:30 PM1:30 PM
Session Overview
Yukari C. Manabe
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
773 - Efficiency of Portable Chest X-Ray Compared to Symptom-Based TB Screening in Southwest Nigeria
Aderonke V. Agbaje
Institute of Human Virology Nigeria, Abuja, Nigeria
1:38 PM1:38 PM
774 - High Prevalence of Asymptomatic Tuberculosis in an African Cohort of People With HIV (CoVPN 3008-TB)
Asa Tapley
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
775 - The Case for Routine Testing and Empiric Treatment of TB Meningitis in High HIV-Prevalence Settings
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
1:46 PM1:46 PM
776 - Very Promising New Urinary LAM Assay for Tuberculosis Diagnosis in Children
Adeline Riondel
French National Institute of Health and Medical Research (Inserm), Paris, France
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Advancing Mental Health for Youth With HIV
1:30 PM1:30 PM
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
1:34 PM1:34 PM
871 - Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
872 - Implementation of a Mental Health Intervention for Youth With HIV in Kenya
Pamela Kohler
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
874 - Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
1:46 PM1:46 PM
873 - Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Some Assembly Required: Self-Blood Collection and Testing
1:30 PM1:30 PM
Session Overview
Michelle Rodolph
World Health Organization, Geneva, Switzerland
1:34 PM1:34 PM
975 - Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa
Alexandra de Nooy
Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
1:38 PM1:38 PM
974 - HIV Self-Testing by Motorcycle-Taxi Drivers: A Novel Approach for Case Detection in Kampala, Uganda
Edith Namulema
Mengo Hospital, Kampala, Uganda
1:42 PM1:42 PM
977 - Virtual Submission of HIV Viral Load in EPI-LoVE, a Digital Cohort of People Living With HIV in US
Pamina M. Gorbach
University of California Los Angeles, Los Angeles, CA, USA
1:46 PM1:46 PM
976 - Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms
David Closs
Friends for All, Memphis, TN, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Masters of Immunity: The Many Faces of T Cells
4:00 PM4:00 PM
36 - Nonconventional T Cells: Functional Shape Shifters and Conductors of Cytokine Orchestras That Dance With Herpesviruses in People With HIV
Jennifer Snyder-Cappione
Boston University, Boston, MA, USA
4:20 PM4:20 PM
37 - The T-Cell Identity: Conventional T Cells in Action
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
4:40 PM4:40 PM
38 - Engineering T Cells: Improving on Nature
Anjie Zhen
University of California Los Angeles, Los Angeles, CA, USA
5:00 PM5:00 PM
Questions and Answers
Pamela J. Skinner
University of Minnesota, Minneapolis, MN, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Time for a Paradigm Shift for Young Pregnant and Breastfeeding Cisgender Women
4:00 PM4:00 PM
39 - HIV Prevention and Treatment Among Young Mothers: Dynamics of Biologic, Psychosocial, and Structural Determinants Across the Life Course
Elona Toska
University of Cape Town, Cape Town, South Africa
4:20 PM4:20 PM
40 - Continuity of Care During Pregnancy and Postpartum
Aleny Couto
Ministry of Health of Mozambique, Maputo, Mozambique
4:40 PM4:40 PM
41 - Ethical and Regulatory System Changes for the Inclusion of Pregnant Women in HIV Research and Development
Cordelia Katureebe
Ministry of Health Uganda, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Lynn T. Matthews
Yale University, New Haven, CT, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Hot Takes on the Clinical Highlights From CROI 2026
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Joseph J. Eron, Jr
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Fatima Kakkar
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Chloe M. Orkin
Queen Mary University of London, London, UK
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Deborah Persaud
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Paul E. Sax
Brigham and Women's Hospital, Boston, MA, USA
FEB25
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 6
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
Previous:
FEB22
8:30 AMto12:30 PMMST
12:00 PMto5:00 PMMST
Scott M. Hammer Workshop for New Researchers and Trainees
8:30 AM8:30 AM
1 - Welcome and Session Overview for the Scott M. Hammer Workshop for New Researchers and Trainees
8:35 AM8:35 AM
Community Perspectives Video
Brian Minalga (Miss Molly Moon)
Fred Hutchinson Cancer Center, Seattle, WA, USA
8:40 AM8:40 AM
What Has the Advent of Capsid Inhibitors Taught Us About HIV Pathogenesis: Navigating Virology Presentations at CROI 2026
Stuart J. D. Neil
King's College London, London, UK
9:03 AM9:03 AM
Questions and Answers
9:18 AM9:18 AM
Community Perspectives Video
Sekgabo Seselamarumo
Sentebale, Gaborone, Botswana
9:23 AM9:23 AM
Immunology of HIV Cure and Beyond: Navigating Immunology Presentations at CROI 2026
John Frater
University of Oxford, Oxford, UK
9:46 AM9:46 AM
Questions and Answers
10:16 AM10:16 AM
Community Perspectives Video
Chilufya Kasanda
CIDRZ (Centre for Infectious Disease Research in Zambia), Lusaka, Zambia
10:21 AM10:21 AM
Long-Acting HIV Treatment Regimens: Where Are We and Where Are We Going? Navigating HIV Treatment Presentations at CROI 2026
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
10:44 AM10:44 AM
Questions and Answers
10:59 AM10:59 AM
Community Perspectives Video
Ricardo Baruch Domninguez
Inspira Cambio A.C., Mexico City, Mexico
11:04 AM11:04 AM
Taking Prevention to the Population Level: Navigating Implementation Science Presentations at CROI 2026
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, USA
11:27 AM11:27 AM
Questions and Answers
11:52 AM11:52 AM
Community Perspectives Video
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
11:57 AM11:57 AM
Reclaiming the Narrative: Navigating Research Through Turbulent Times
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
12:20 PM12:20 PM
Community Perspectives Video
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Laboratory Sciences
2:00 PM2:00 PM
2 - Spatial Transcriptomic and Proteomic Profiling of HIV in Tissues
Zaza Ndhlovu
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
3 - Integrative Structural and Computational Approaches to RNA Biology
Megan Ken
The Scripps Research Institute, La Jolla, CA, USA
3:00 PM3:00 PM
4 - Latent HIV Reversal via Functional Genomics and Single-Cell Perturbation Modeling
Wei Li
University of Maryland, Baltimore, MD, USA
3:30 PM3:30 PM
5 - Leveraging Artificial Intelligence for Spatial Analysis of Infectious Diseases
Jacob D. Estes
Oregon Health & Science University, Portland, OR, USA
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Contemporary Issues in Clinical Management: A Case-Based Workshop
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Sanjay Bhagani
Royal Free London NHS Foundation Trust, London, UK
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Brenda E. Crabtree-Ramírez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
2:00 PM2:00 PM
6 - Case Presentation With Panel Discussion, Plus Questions and Answers From the Audience
Susanna Naggie
Durham VA Health Care System, Durham, NC, USA
FEB22
2:00 PMto4:00 PMMST
12:00 PMto5:00 PMMST
Clinical Trial Design and Analysis Workshop
2:00 PM2:00 PM
7 - Clinical Trials in the Post-Lenacapavir Era
David V. Glidden
University of California San Francisco, San Francisco, CA, USA
2:35 PM2:35 PM
8 - Measurement of Outcomes in Health Care Delivery: Implementation Trials
Thomas A. Odeny
Washington University, St Louis, MO, USA
3:10 PM3:10 PM
9 - Accounting for User Choice: Preference Trials in HIV Prevention and Treatment Research
Elizabeth R. Brown
Fred Hutchinson Cancer Center, Seattle, WA, USA
FEB22
5:00 PMto7:00 PMMST
12:00 PMto5:00 PMMST
Opening Session
5:00 PM5:00 PM
Welcome From the Conference Chair
Nicolas Chomont
Université de Montréal, Montreal, Canada
5:10 PM5:10 PM
Introduction to the Lifetime Achievement Award
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
5:15 PM5:15 PM
Acceptance of the Lifetime Achievement Award
Carl W. Dieffenbach
Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
5:20 PM5:20 PM
Introduction to the Bernard Fields Lecture
Nicolas Chomont
Université de Montréal, Montreal, Canada
5:25 PM5:25 PM
10 - Unfinished Business: Thirty Years of Persistence, Progress, and Partnerships in HIV Cure Science
Sharon R. Lewin
The University of Melbourne, Melbourne, Australia
5:50 PM5:50 PM
Introduction to the Martin Delaney Presentation
Michael Louella
UW/Fred Hutch Center for AIDS Research (CFAR), Seattle, WA, USA
5:55 PM5:55 PM
11 - ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding
Peter Staley
PrEP4All, New York, NY, USA
6:20 PM6:20 PM
Introduction to the N'Galy-Mann Lecture
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
6:25 PM6:25 PM
12 - The ART of Prevention: People, Science, Progress
Linda-Gail Bekker
Desmond Tutu HIV Foundation, Cape Town, South Africa
6:50 PM6:50 PM
Conclusion of the Opening Session and Welcome to the Opening Reception
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
FEB22
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
FEB22
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
FEB23
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Peter W. Hunt
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
13 - Meeting the Moment: HIV Treatment and Prevention
Ilesh Jani
Mozambique National Institute of Health, Maputo, Mozambique
9:05 AM9:05 AM
14 - Structure, Function, and Inhibition of the HIV Capsid
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Interaction of HIV With Cells and People
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
100 - Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10:13 AM10:13 AM
101 - Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA
Hisashi Akiyama
Boston University, Boston, MA, USA
10:21 AM10:21 AM
102 - RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:29 AM10:29 AM
103 - Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
104 - Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
11:13 AM11:13 AM
105 - Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
106 - Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
11:29 AM11:29 AM
107 - Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model
Stacey A. Smith
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
108 - Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
10:13 AM10:13 AM
109 - Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation
Paraskevas Filippidis
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
110 - Characterization of HIV Proviruses in Brain Microglia in PWH on ART
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
10:29 AM10:29 AM
111 - Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes
Alan Winston
Imperial College London, London, UK
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
112 - Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
11:13 AM11:13 AM
113 - Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
114 - Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies
Claudia Stroupe
Northwestern University, Chicago, IL, USA
11:29 AM11:29 AM
115 - GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa
Miguel Marin
Africa Health Research Institute, Durban, South Africa
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
116 - Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV
Zaayid Omar
University of Cape Town, Cape Town, South Africa
10:13 AM10:13 AM
117 - Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:21 AM10:21 AM
118 - Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
119 - Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
120 - Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
11:13 AM11:13 AM
121 - Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
11:21 AM11:21 AM
122 - Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:29 AM11:29 AM
123 - Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
11:37 AM11:37 AM
124 - Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB23
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
125 - Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
10:13 AM10:13 AM
126 - MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
10:21 AM10:21 AM
127 - Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
10:29 AM10:29 AM
128 - Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
129 - Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
11:13 AM11:13 AM
130 - Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
11:21 AM11:21 AM
131 - RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:29 AM11:29 AM
132 - Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Mechanisms and Modifiers: Treatable Causes of Cognitive Impairment and Depression
1:30 PM1:30 PM
Session Overview
Leah H. Rubin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
453 - MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study
Katekarn Porkaew
Chulalongkorn University, Bangkok, Thailand
1:38 PM1:38 PM
451 - Metabolic Syndrome and Cognitive Impairment Among Men With and Without HIV
Sara M. Hockney
Northwestern University, Chicago, IL, USA
1:42 PM1:42 PM
448 - Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Female Individuals
Elana Farrell
University of California San Francisco, San Francisco, CA, USA
1:46 PM1:46 PM
447 - The Impact of Semaglutide on Depressive Symptoms Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
New Host Factors: Regulating Nuclear Events of HIV Replication
1:30 PM1:30 PM
Session Overview
Edward Campbell
Loyola University Chicago, Chicago, IL, USA
1:34 PM1:34 PM
217 - BLM Helicase Is Required for Efficient HIV Infection in Macrophages
Andrew Leal
Boston University, Boston, MA, USA
1:38 PM1:38 PM
218 - CD46 Interacts With Sp1 to Control HIV Expression in Infected T Cells
Pavitra Ramdas
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
1:42 PM1:42 PM
216 - Exploring the Role of FUBP1 in HIV Replication and Latency
Fiona Carter-Tod
Northwestern University, Chicago, IL, USA
1:46 PM1:46 PM
214 - Cis- and Trans-Acting Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts
Anthony Boateng
Washington University in St Louis, St Louis, MO, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Noncanonical Mutations Conferring Resistance to InSTIs
1:30 PM1:30 PM
Session Overview
Daniel R. Kuritzkes
Harvard Medical School, Boston, MA, USA
1:34 PM1:34 PM
551 - Env Mutations Are a Gateway for Acquisition of InSTI Resistance
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
1:38 PM1:38 PM
585 - Nucleocapsid Mutations During Virologic Failure of an Integrase Inhibitor-Based Regimen
Charlotte Charpentier
Assistance Publique – Hôpitaux de Paris, Paris, France
1:42 PM1:42 PM
553 - Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure
Nicola Coetzee
Stellenbosch University, Cape Town, South Africa
1:46 PM1:46 PM
550 - Characterization of Mutations Outside the Integrase in HIV-1 Individuals in Whom Dolutegravir Failed
Aurelie Minelle Kengni Ngueko
Centre International de Référence Chantal Biya, Yaoundé, Cameroon
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Sleepless in Denver: Impact of Funding Changes on HIV Care
1:30 PM1:30 PM
Session Overview
Jennifer Kates
Kaiser Family Foundation, Washington, DC, USA
1:38 PM1:38 PM
1051 - Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries
Ellen Brazier
Institute for Implementation Science in Population Health, New York, NY, USA
1:42 PM1:42 PM
1054 - Population-Representative Consequences of Foreign Aid Instability for HIV Services in South Africa
Lindsey Filiatreau
Washington University in St Louis, St Louis, MO, USA
1:46 PM1:46 PM
1107 - Short-Term Poverty Relief and ART Adherence: Insights From a Natural Experiment of SNAP Recipients
Aaron Richterman
University of Pennsylvania, Philadelphia, PA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
In and Out of the Capsid
4:00 PM4:00 PM
5-Minute Moderator Opening: Background and Setting the Stage
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
4:05 PM4:05 PM
15 - Integrase Anchors Viral RNA to the HIV-1 Capsid Interior
Peter Cherepanov
The Francis Crick Institute, London, UK
4:25 PM4:25 PM
16 - Capsid-Mediated Protection of HIV-1 Nucleic Acids From Innate Immune Detection
Sebla Kutluay
Washington University in St Louis, St Louis, MO, USA
4:45 PM4:45 PM
17 - HIV-1 Uncoating Site Dictates Sites of Integration
Vinay K. Pathak
National Cancer Institute at Frederick, Frederick, MD, USA
5:05 PM5:05 PM
Questions and Answers
Theodora Hatziioannou
Rockefeller University, New York, NY, USA
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV
4:00 PM4:00 PM
18 - Neurodegeneration and Dementia Risk in Older Adults With HIV: Biomarkers and Epidemiology
Alan Winston
Imperial College London, London, UK
4:20 PM4:20 PM
19 - Epigenetic Aging of the Brain in HIV: Methylation Clocks and Antiretroviral-Related Changes
Michael J. Corley
University of California San Diego Medical Center, La Jolla, CA, USA
4:40 PM4:40 PM
20 - Cognitive Aging in HIV: Clinical Assessment and Management
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Questions and Answers
Paola M. P. Cinque
IRCCS San Raffaele Scientific Institute, Milan, Italy
FEB23
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Strategic and Resilient Responses to the Funding Crisis Across Africa
4:00 PM4:00 PM
21 - Sustaining Successful HIV Programs Across Africa: The Impact of Shifts in Funding
Geoff P. Garnett
London School of Hygiene & Tropical Medicine, London, UK
4:20 PM4:20 PM
22 - Global Cuts, Local Consequences: Community Impact and Response to the HIV Funding Crisis
Solange L. Baptiste
ITPC Global, Johannesburg, South Africa
4:40 PM4:40 PM
23 - Circumventing the Cascading Crisis: Impacts of US Government Policies on Research and Adaptations in Africa
Andrew D. Kambugu
Infectious Disease Institute, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestLastName 4
Institution 4
FEB23
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestLastName 2
Institution 2
FEB24
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
24 - GLP-1 Receptor Agonists: Are They a Cure for Everything?
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9:05 AM9:05 AM
25 - Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
133 - A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
10:13 AM10:13 AM
134 - Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B
Julia Edgar
University of Oxford, Oxford, UK
10:21 AM10:21 AM
135 - Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control
Katie Fisher
Aarhus University, Aarhus, Denmark
10:29 AM10:29 AM
136 - Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
137 - CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
11:13 AM11:13 AM
138 - Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
139 - Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
140 - Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
141 - Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results
David Wyles
Denver Health Medical Center, Denver, CO, USA
10:13 AM10:13 AM
142 - Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy
Grace Haser
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
143 - Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
144 - Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
145 - One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
11:13 AM11:13 AM
146 - Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis
Sean Wasserman
St George's University of London, London, UK
11:21 AM11:21 AM
147 - DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
11:29 AM11:29 AM
148 - Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
11:37 AM11:37 AM
149 - Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
150 - DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
151 - Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
10:21 AM10:21 AM
152 - Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
153 - Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
154 - DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
11:13 AM11:13 AM
155 - Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
11:21 AM11:21 AM
156 - Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention
Brian Zanoni
Emory University, Atlanta, GA, USA
11:29 AM11:29 AM
157 - Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
We Thought You'd Never Ask: Improving HIV Screening and Testing
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
158 - Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
10:13 AM10:13 AM
159 - Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers
Timothy Long MD
Health Choice Network, Miami, FL, USA
10:21 AM10:21 AM
160 - Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US
David E. Hudon
Prisma Health, Greenville, SC, USA
10:29 AM10:29 AM
161 - Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
162 - Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025
Andrew Hill
University of Liverpool, Liverpool, UK
11:13 AM11:13 AM
163 - The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
164 - Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial
Paul K. Drain
University of Washington, Seattle, WA, USA
11:29 AM11:29 AM
165 - Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Targeting the HIV Reservoir: Novel Cure Strategies
1:30 PM1:30 PM
Session Overview
Marina Caskey
The Rockefeller University, New York, NY, USA
1:34 PM1:34 PM
406 - Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles
Keely Gliwa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo
David D. Ho
Aaron Diamond AIDS Research Center, New York, NY, USA
1:42 PM1:42 PM
407 - Combination Therapy With Tat mRNA and a TLR9 Agonist Delays Post-ATI Rebound in the NHP Model
Takuto Nogimori
National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
1:46 PM1:46 PM
408 - Markedly Reduced Mutability of Networked Epitopes Promotes CTL Clearance of the Latent HIV Reservoir
Fernando B. Senjobe
Harvard Medical School, Boston, MA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Extra Large Challenges in Steatotic Liver Disease
1:30 PM1:30 PM
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
599 - Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
1:38 PM1:38 PM
600 - Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
1:42 PM1:42 PM
598 - Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
1:46 PM1:46 PM
601 - Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV
Jimmy Ma
University of Washington, Seattle, WA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Precision Comes to Public Health
1:30 PM1:30 PM
Session Overview
Suzue Saito
ICAP at Columbia University, New York, NY, USA
1:34 PM1:34 PM
903 - Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia
Michael Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:38 PM1:38 PM
890 - Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina
Ann Dennis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:42 PM1:42 PM
894 - Mapping Recent HIV Infections Among MSM in Thailand: Data-Driven Insights for Targeted Prevention
Michael Reid
1:46 PM1:46 PM
922 - Progress Towards HIV Epidemic Control Among Young Key Populations in India
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Machines, Models, and Messages
1:30 PM1:30 PM
Session Overview
Ravi Goyal
University of California San Diego, La Jolla, CA, USA
1:34 PM1:34 PM
1077 - Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025
Ndinda Christian
Rwanda Biomedical Centre, Kigali, Rwanda
1:38 PM1:38 PM
1076 - Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits
Joseph W. Hogan
Brown University, Providence, RI, USA
1:42 PM1:42 PM
1079 - Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya
Jessica Haberer
Massachusetts General Hospital, Boston, MA, USA
1:46 PM1:46 PM
1078 - Measuring Provider Quality of Care in Tanzania Using Large Language Models
Alaa Abdellatif
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
30 Years of Viral Suppression: A Biologic Reset?
4:00 PM4:00 PM
26 - HIV Reservoir: Persistence and Expansion Under Long-Term ART
John W. Mellors
University of Pittsburgh, Pittsburgh, PA, USA
4:20 PM4:20 PM
27 - HIV-Specific T-Cell Responses in People With HIV on Long-Term ART
Victor Appay
University of Bordeaux, Bordeaux, France
4:40 PM4:40 PM
28 - Beyond Undetectable: Chronic Inflammation and Multimorbidity in People With HIV on ART
Irini Sereti
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
5:00 PM5:00 PM
Questions and Answers
Michael M. Lederman
Case Western Reserve University, Cleveland, OH, USA
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
The Long Game: Progress and the Promise of Long-Acting ART for Treatment
4:00 PM4:00 PM
29 - Clinical Trials and New Drugs in the Pipeline
Onyema Ogbuagu
Yale University, New Haven, CT, USA
4:20 PM4:20 PM
30 - Challenges and Solutions to Implementation
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
4:40 PM4:40 PM
Panel Discussion
Eric S. Daar
University of California Los Angeles, Los Angeles, CA, USA
4:40 PM4:40 PM
Panel Discussion
Gastón Devisich
Fundación Huésped, Buenos Aires, Argentina
4:40 PM4:40 PM
Panel Discussion
Rosie Mngqibisa
Enhancing Care Foundation, Durban, South Africa
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Counting and Caring for Transgender and Gender-Diverse Individuals
4:00 PM4:00 PM
31 - Epidemiology
Stefan Baral
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:20 PM4:20 PM
32 - Clinical Management
Asa E. Radix
Callen-Lorde Community Health Center, New York, NY, USA
4:40 PM4:40 PM
33 - Community Evidence, System Change: Transgender Leadership in Sustaining HIV Care
Rena Janamnuaysook
Institute of HIV Research and Innovation, Bangkok, Thailand
5:00 PM5:00 PM
Questions and Answers
Jade Ghosn
Assistance Publique – Hôpitaux de Paris, Paris, France
FEB24
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
FEB25
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Wednesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
8:35 AM8:35 AM
34 - Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
9:05 AM9:05 AM
35 - Tuberculosis in Children and Adolescents: From Neglect to Action
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Manipulating the HIV Immune Response for Prevention and Treatment
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
166 - Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:13 AM10:13 AM
167 - Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
168 - In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
169 - Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
170 - Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:13 AM11:13 AM
171 - A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
172 - Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:29 AM11:29 AM
173 - Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART
Mirko Paiardini
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Extending the Reach: Long-Acting Antiviral and Novel Delivery
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
174 - Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
10:13 AM10:13 AM
175 - Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing
Nilay Thakkar
GSK plc, Collegeville, PA, USA
10:21 AM10:21 AM
176 - Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back
GSK plc, Collegeville, PA, USA
10:29 AM10:29 AM
177 - DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
178 - Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
11:13 AM11:13 AM
179 - Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
11:21 AM11:21 AM
180 - Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
181 - Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1
Chloe M. Orkin
Queen Mary University of London, London, UK
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Good to Great: Advancing Treatment and Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
182 - HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
10:13 AM10:13 AM
183 - Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
10:21 AM10:21 AM
184 - The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants
Adam W. Carrico
Florida International University, Miami, FL, USA
10:29 AM10:29 AM
185 - Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma
Kathleen J. Sikkema
Columbia University, New York, NY, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
186 - SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
11:13 AM11:13 AM
187 - Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation
Deborah Hoege
Georgetown University, Washington, DC, USA
11:21 AM11:21 AM
188 - Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
11:29 AM11:29 AM
189 - Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial
Chris T. Longenecker
University of Washington, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Partners, Pills, and Penicillin: Progress in Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
190 - Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25
Chase A. Cannon
University of Washington, Seattle, WA, USA
10:13 AM10:13 AM
191 - HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
192 - HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
10:29 AM10:29 AM
193 - Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
194 - Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
11:13 AM11:13 AM
195 - Early Syphilis and HIV Among Adolescents: United States, 20142-023
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:21 AM11:21 AM
196 - Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
11:29 AM11:29 AM
197 - Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men
Kate L. Seib
Griffith University, Southport, Australia
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Harnessing B-Cells and Antibodies for HIV Control
1:30 PM1:30 PM
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
1:34 PM1:34 PM
294 - AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques
Luanna E. L. Vidal
University of Miami, Miami, FL, USA
1:38 PM1:38 PM
295 - Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
1:42 PM1:42 PM
296 - Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control
Elif Cakan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:46 PM1:46 PM
297 - Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI
Julia A. Wagner
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Tuberculosis: Innovative Screening and Diagnostic Approaches
1:30 PM1:30 PM
Session Overview
Yukari C. Manabe
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
773 - Efficiency of Portable Chest X-Ray Compared to Symptom-Based TB Screening in Southwest Nigeria
Aderonke V. Agbaje
Institute of Human Virology Nigeria, Abuja, Nigeria
1:38 PM1:38 PM
774 - High Prevalence of Asymptomatic Tuberculosis in an African Cohort of People With HIV (CoVPN 3008-TB)
Asa Tapley
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
775 - The Case for Routine Testing and Empiric Treatment of TB Meningitis in High HIV-Prevalence Settings
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
1:46 PM1:46 PM
776 - Very Promising New Urinary LAM Assay for Tuberculosis Diagnosis in Children
Adeline Riondel
French National Institute of Health and Medical Research (Inserm), Paris, France
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Advancing Mental Health for Youth With HIV
1:30 PM1:30 PM
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
1:34 PM1:34 PM
871 - Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
872 - Implementation of a Mental Health Intervention for Youth With HIV in Kenya
Pamela Kohler
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
874 - Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
1:46 PM1:46 PM
873 - Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Some Assembly Required: Self-Blood Collection and Testing
1:30 PM1:30 PM
Session Overview
Michelle Rodolph
World Health Organization, Geneva, Switzerland
1:34 PM1:34 PM
975 - Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa
Alexandra de Nooy
Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
1:38 PM1:38 PM
974 - HIV Self-Testing by Motorcycle-Taxi Drivers: A Novel Approach for Case Detection in Kampala, Uganda
Edith Namulema
Mengo Hospital, Kampala, Uganda
1:42 PM1:42 PM
977 - Virtual Submission of HIV Viral Load in EPI-LoVE, a Digital Cohort of People Living With HIV in US
Pamina M. Gorbach
University of California Los Angeles, Los Angeles, CA, USA
1:46 PM1:46 PM
976 - Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms
David Closs
Friends for All, Memphis, TN, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Masters of Immunity: The Many Faces of T Cells
4:00 PM4:00 PM
36 - Nonconventional T Cells: Functional Shape Shifters and Conductors of Cytokine Orchestras That Dance With Herpesviruses in People With HIV
Jennifer Snyder-Cappione
Boston University, Boston, MA, USA
4:20 PM4:20 PM
37 - The T-Cell Identity: Conventional T Cells in Action
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
4:40 PM4:40 PM
38 - Engineering T Cells: Improving on Nature
Anjie Zhen
University of California Los Angeles, Los Angeles, CA, USA
5:00 PM5:00 PM
Questions and Answers
Pamela J. Skinner
University of Minnesota, Minneapolis, MN, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Time for a Paradigm Shift for Young Pregnant and Breastfeeding Cisgender Women
4:00 PM4:00 PM
39 - HIV Prevention and Treatment Among Young Mothers: Dynamics of Biologic, Psychosocial, and Structural Determinants Across the Life Course
Elona Toska
University of Cape Town, Cape Town, South Africa
4:20 PM4:20 PM
40 - Continuity of Care During Pregnancy and Postpartum
Aleny Couto
Ministry of Health of Mozambique, Maputo, Mozambique
4:40 PM4:40 PM
41 - Ethical and Regulatory System Changes for the Inclusion of Pregnant Women in HIV Research and Development
Cordelia Katureebe
Ministry of Health Uganda, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Lynn T. Matthews
Yale University, New Haven, CT, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Hot Takes on the Clinical Highlights From CROI 2026
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Joseph J. Eron, Jr
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Fatima Kakkar
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Chloe M. Orkin
Queen Mary University of London, London, UK
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Deborah Persaud
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Paul E. Sax
Brigham and Women's Hospital, Boston, MA, USA
FEB25
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 6
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
